RecruitingNot ApplicableNCT04455932

HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation


Sponsor

Concord Repatriation General Hospital

Enrollment

476 participants

Start Date

Jan 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

All international guidelines recommend 6-monthly ultrasound surveillance for patients at risk for liver cancer (hepatocellular carcinoma or HCC), such as patients with cirrhosis. The aim of surveillance is to detect HCC at an early stage when it is still potentially curable. Currently only 4 out of 10 HCCs are detected at the early stage. Ultrasound surveillance for HCC has a wide ranging sensitivity, dependent on many factors such as operator experience, patient body habitus and liver parenchymal heterogeneity due to chronic liver disease and cirrhosis. In a select group of patients, surveillance ultrasound can be suboptimal or near non-diagnostic. Currently no guideline offers an alternative surveillance tool for patients who have suboptimal surveillance ultrasounds.


Eligibility

Min Age: 20 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing two methods for monitoring liver cancer in patients with cirrhosis (scarring of the liver) who have poor-quality ultrasound images. It compares a shorter, non-contrast MRI scan to the standard ultrasound to see which better detects early liver cancer. **You may be eligible if:** - You have cirrhosis (liver scarring) from any common cause - Your liver is difficult to see clearly on standard ultrasound - You have no current or past signs of liver cancer (hepatocellular carcinoma) - You are able to attend regular follow-up appointments **You may NOT be eligible if:** - You have a pacemaker, defibrillator, metallic implant, or severe claustrophobia that prevents an MRI scan - You have already been diagnosed with liver cancer or are currently being investigated for it - You have had a liver transplant - You have significant kidney problems that prevent contrast dye use (if applicable) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTAbbreviated non-contrast MRI of the liver

every 6 months

DIAGNOSTIC_TESTUltrasound surveillance

every 6 months

DIAGNOSTIC_TESTMultiphase contrast-enhanced liver MRI

screening


Locations(10)

Royal Prince Alfred Hospital

Camperdown, New South Wales, Australia

Concord Repatriation General Hospital

Concord, New South Wales, Australia

Gosford Hospital

Gosford, New South Wales, Australia

Prince of Wales Hospital

Randwick, New South Wales, Australia

Westmead Hospital

Westmead, New South Wales, Australia

Princess Alexandra Hospital

Brisbane, Queensland, Australia

St Vincent's Hospital Melbourne

Fitzroy, Victoria, Australia

Austin Hospital

Heidelberg, Victoria, Australia

Royal Perth Hospital

Perth, Western Australia, Australia

North Shore Hospital

Takapuna, Auckland, New Zealand

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04455932


Related Trials